Intellia Therapeutics, Inc. (NTLA), Wednesday announced that the U.S. Food and Drug Administration has granted Regenerative Medicine Advanced Therapy designation to nexiguran ziclumeran, also known as nex-z or NTLA-2001, for the treatment of transthyretin or TTR amyloidosis with cardiomyopathy.
The designation was based on the findings of interim Phase 1 clinical data, which demonstrated that the administration of nex-z led to consistent, deep and long-lasting TTR reduction.
Nex-z has been granted the designations by the U.S. FDA for both cardiomyopathy and polyneuropathy, where it showed unprecedented rapid, durable and consistent reductions in serum TTR after a single dose.
Nex-z has also been granted Orphan Drug Designation by the U.S. FDA and European Commission.
In the pre-market hours, Intellia's stock is trading at $8.90, up 1.95 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.